Case report

Cerebral venous sinus thrombosis as the initial presentation of essential thrombocythemia - A case report and literature review

Qudsum Yousaf a, Haseeb Amad Khan b, Fateen Ata c,*, Adeel Ahmad Khan d, Nadia Karim c, Zohaib Yousaf c

a Department of Neurology, Central Park Teaching Hospital, Lahore, Pakistan
b Department of Internal Medicine, Nishtar Medical College and Hospital, Multan, Pakistan
c Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
d Department of Endocrinology, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar

ARTICLE INFO

Keywords:
Myeloproliferative disorders
Cerebral venous sinus thrombosis
Essential thrombocythemia
Stroke

ABSTRACT

Myeloproliferative disorders (MPD) are associated with vascular thrombosis. Common sites for thrombosis are large arteries; however, less commonly, cerebral venous sinus thrombosis (CVST) has also been reported. It is rare to have CVST as an initial presentation of MPD. We discuss a male patient in whose presentation due to CVST led to the diagnosis of essential thrombocythemia (ET). Furthermore, we performed a literature review to evaluate the association of CVST with ET.

1. Introduction

Cerebral venous sinus thrombosis (CVST) is an uncommon type of stroke, which is frequent in females (3:1) [1]. It accounts for 0.5% of all strokes [2]. Myeloproliferative disorders (MPD) can rarely present as CVST as their initial manifestation [3]. Typical sites of thrombosis in MPD are large arteries. Among MPD, polycythemia vera and essential thrombocythemia (ET) have shown an association with thrombosis at atypical sites such as cerebral venous sinuses and splanchnic vein [4]. Common mutations in ET are Janus kinase (JAK2) and calreticulin (CALR.). Thrombotic sequelae are more commonly associated with JAK2 mutation [5].

ET is diagnosed based on the World Health Organization criteria [6]. The criteria consist of a sustained platelet count $\geq 450 \times 10^9$/L, the presence of an acquired pathogenetic mutation, absence of other myeloid malignancy, an absence of a reactive cause for thrombocytosis, and normal iron stores. There is an increased production of platelets in ET, which might be responsible for the prothrombotic state leading to thrombosis, e.g., CVST. Prompt diagnosis and management of CVST are crucial for having favorable outcomes in ET [7]. CVST affects 4 per million adults, predominantly affecting adults in their 30s and 40s, and 7 per million pediatric population [8].

We report a 37-year-old presenting with CVST and was later found to have underlying ET. The case is accompanied by a literature review of the previously reported cases on the topic [3,9–13].

2. Case presentation

A 37-year-old previously healthy Pakistani male presented with a persistent, moderately severe, bilateral frontal and occipital headache for four months. The headache was not associated with nausea, vomiting, fever, photophobia, or neck stiffness. The patient did not seek medical advice and used over-the-counter analgesics for pain without much relief. The headache was associated with the heaviness of the head. The patient also developed a painless, progressive blurring of vision two weeks after headache onset. The blurring of vision was initially in the left eye and then involved the right eye—no previous similar episodes were noted. There was no associated fever, rash, joint pain, photosensitivity, photophobia, burning micturition, cough, night sweats, diarrhea, or weight loss. A complete review of systems was unremarkable.

Upon presentation, the patient was afebrile (36.3 °C), normotensive (127/83 mmHg), had a heart rate of 83 beats per minute, a respiratory rate of 17 breaths per minute, and saturated well on room air. He was conscious, alert, oriented with a Glasgow coma scale of 15/15. The neurological examination revealed a normal motor, sensory and cerebellar exam. Cranial nerve examination revealed a visual acuity of 6/24 in the right eye and finger counting with a positive rapid afferent
pupillary defect (RAPD) in the left eye. Fundoscopy revealed bilateral grade 3 papilledema. The rest of the clinical examination was unremarkable.

Initial investigations, including a complete blood count, electrolytes, renal function test, liver function test, thyroid function test, and coagulation profile, revealed thrombocytosis ($1327 \times 10^3$ per microliter) and prolonged bleeding time. (Table 1) A peripheral smear confirmed the presence of thrombocytosis along with platelet anisocytosis.

A non-contrast CT of the head was done prior to lumbar puncture (LP) and was unremarkable. The opening pressure of CSF was 40 cm of water, and 30 ml was drained. The CSF examination was within normal limits. (Table 1) After the LP, the headache resolved, and the vision in the right eye improved, but there was no improvement in the left eye vision. Magnetic resonance imaging (MRI) and magnetic resonance venography (MRV) was done and showed extensive cerebral venous sinus thrombosis, including the superior sagittal sinus and bilateral lateral and sigmoid sinuses. (Fig. 1).

A bone marrow biopsy was performed considering the possibility of a myeloproliferative neoplasm, which revealed active erythropoiesis and myelopoiesis with prominent megakaryocytic hyperplasia. The biopsy was consistent with essential thrombocythemia. JAK2 V617F mutation was positive with a negative BCR-ABL. A multidisciplinary meeting was held between radiology, neurology, and hematology, and a formal diagnosis of CVST secondary to ET was made. The patient was initiated on aspirin 100 mg daily, hydroxyurea 500 mg twice daily, and rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg daily. On a three-month follow-up, the patient’s platelets normalized, his headache resolved completely; however, the blurring of vision persisted. The patient did not develop any anticoagulation related complications. Patient was advised for life-long anticoagulation in view of persistent risk factor (ET) for his CVST. However, after the first follow-up, the patient was lost to further follow-ups.

3. Discussion

Essential thrombocythemia is a myeloproliferative disorder with autonomous/primary thrombocytosis. In descending frequency, neurological complications associated with ET include cephalalgia, chronic paresthesia, dizziness or hypotension, visual disturbances, and tinnitus [14]. Venous thromboembolism associated with MPD presents commonly as DVT and uncommonly as splanchnic vein thrombosis [15]. CVST is relatively rare in association with MPD.

Table 1

| Variable                        | Values | Reference ranges |
|---------------------------------|--------|-----------------|
| White cells (per mm3)           | 7.6    | 4.5-10          |
| Platelet count (10^9/L)         | 1327   | 150-400         |
| Hemoglobin (gm/Liter)           | 15     | 14-18           |
| ESR (mm/1st hour)               | 28     | 1-13            |
| Total Bilirubin (mg/dL)         | 0.7    | 0.3-1           |
| Total protein (g/Liter)         | 78     | 60-83           |
| Albumin (g/Liter)               | 41     | 34-54           |
| Alkaline Phosphatase (Unit/Liter)| 215 | 38-126         |
| Alanine Aminotransferase (Unit/Liter)| 27 | 0-35          |
| Aspartate Aminotransferase (Unit/Liter)| 38 | 17-59         |
| Glucose (mmol/L)                | 8.2    | 3.9-5.5         |
| Urea (mmol/L)                   | 3.8    | 2.1-8.5         |
| Creatinine (Umol/Liter)         | 62     | 61.9-114.9      |
| Sodium                          | 134    | 135-145         |
| Potassium (mmol/L)              | 3.4    | 3.6-5.2         |
| Chloride (mmol/L)               | 102    | 96-106          |
| Bicarbonate (mmol/L)            | 23     | 23-29           |
| Corrected Calcium (mmol/L)      | 2.23   | 2.2-2.5         |
| Bleeding time (minutes, seconds)| 2 min, 15 s | 2-7 min |
| aPTT (seconds)                  | 48     | 21-25           |
| INR                             | 1.1    | <1.1            |
| PT (seconds)                    | 15     | 10-13           |
| TSH (mIU/L)                     | 2.1    | 0.4-4           |
| fT4 (ng/dL)                     | 1.5    | 0.7-1.9         |

| CSF (Lumbar Puncture)           |       |                 |
| Appearance                      | Clear  | –                |
| Xanthochromia                   | Negative| –               |
| Red blood cells (number)        | Nil    | 0               |
| White blood cells (number)      | Nil    | <3              |
| Protein (mg/dL)                 | 20     | 15-60           |
| Glucose (mmol/L)                | 4      | 2.5-3.5         |

A-E: Magnetic resonance imaging (MRI) and magnetic resonance venography (MRV) images showing extensive cerebral venous sinus thrombosis, including the superior sagittal sinus and bilateral lateral and sigmoid sinuses. (Fig. 1.)

Fig. 1. A-E: Magnetic resonance imaging (MRI) and magnetic resonance venography (MRV) images showing extensive cerebral venous sinus thrombosis, including the superior sagittal sinus and bilateral lateral and sigmoid sinuses.
| Author                  | Year | Age (Y) | Gender (F/M) | Cell line involved | Highest platelets (*10^9/L) | Site of thrombosis                                                                 | CVST as initial presentation | Anticoagulation | Hydroxyurea | Aspirin | Other treatment | Prognosis                                                                                     |
|------------------------|------|---------|--------------|--------------------|-----------------------------|----------------------------------------------------------------------------------|-------------------------------|----------------|-------------|---------|----------------|---------------------------------------------------------------------------------------------|
| Jensen AW et al.       | 2007 | 15, M   |              | Platelets          | 1197                        | Left transverse sinus, sigmoid sinus, and vein of Labbe                            | Yes                           | Warfarin       | Yes         | Yes     | NA             | Follow-up after six months showed progressive recanalization of the left transverse sinus and his symptoms resolved. Good with cytoreduction and anti-thrombotic therapy until the patient discontinued medication after 4 years. Two months later, he experienced second attack. |
| Chen WB et al.         | 2018 | 33, M   |              | Platelets          | 457–593                     | Superior sagittal sinus, straight sinus, and bilateral transverse sinus            | Yes                           | LMWH followed by warfarin | Yes         | Yes       | NA             | NA                                                                                          |
| Chen WB et al.         | 2018 | –       |              | Platelets          | 181                         | Superior sagittal sinus, straight sinus, and bilateral transverse sinus            | Yes                           | No             | No          | Yes     | NA             | NA                                                                                          |
| Chen WB et al.         | 2018 | 34, F   |              | Platelets          | 350–593                     | Superior sagittal sinus, straight sinus, and bilateral transverse sinus            | Yes                           | LMWH Warfarin | No          | Yes     | Interferon-alpha | Good with cytoreduction and anti-thrombotic therapy in next six years                        |
| Chen WB et al.         | 2018 | 71, M   |              | Platelets          | 460–759                     | Superior sagittal sinus, straight sinus, and bilateral transverse sinus            | Yes                           | LMWH Warfarin | Denied Cytoreduction | Yes     | NA             | He denied cytoreduction. His symptoms improved slowly, and no thrombotic event was observed in the subsequent six years. Favorable long-term outcomes with anti-thrombotic and cytoreduction – |
| Chen WB et al.         | 2018 | 43, M   |              | Platelets          | 456                         | Superior sagittal, right transverse, and sigmoid sinus                            | Yes                           | LMWH Warfarin | NA          | NA      | Selective thrombolysis and endovascular thrombectomy | At 2 years follow up, long term HU therapy planned to prevent thrombosis (continued on next page) |
| Chen WB et al.         | 2018 | –       |              | Platelets          | 352–506                     | –                                                                               | Yes                           | LMWH Warfarin | Yes         | Yes     | Endovascular thrombectomy | –                                                                                           |
| Kurosawa H et al.      | 2009 | 6, F    |              | Platelets          | 680                         | Superior sagittal, right transverse sinus and sigmoid sinus                       | Yes                           | NA             | Initially, HU was not administered. But later started due to recurrent thrombosis | Yes     | NA             | At 2 years follow up, long term HU therapy planned to prevent thrombosis (continued on next page) |

(continued on next page)
A literature review on PubMed using Boolean operator strategy of: (Essential thrombocythemia) AND ((CVST) OR (Cerebral Venous sinus thrombosis)) performed on the 25th of November 2021 revealed 16 articles. Nine studies were excluded after screening the titles. Abstracts were reviewed for seven articles, and one more article was removed as it was not relevant [3,9,16]. Clinical characteristics, management, and outcomes of the reported cases of CVST secondary to ET are summarized in Table 2 which also summarizes our case in the last row.

The median age of presentation of previously published cases is 34 years, with a female preponderance (55%). This female preponderance depends upon the etiology of CVST [2]. New Oral Anticoagulants (NOACs) such as Rivaroxaban are being studied for their safety and efficacy in CVST. Currently, the data is limited to case reports, retrospective studies, and small trials. However, the results concerning efficacy seem to be similar to warfarin in CVST [17–19]. A recent systematic review has reported adequate efficacy and safety of NOACs compared to warfarin in CVST, with uncertainties persisting in dosing and duration of treatment [20]. Bose et al. reported the mean duration of 8.1 months for NOACs compared to 9.8 months with standard therapy [20]. However, current guidelines await more extensive randomized trials and meta-analyses on NOACs in CVST before adding them into its management guidelines [21]. Until more evidence is available, NOACs should be used in CVST in cases where warfarin use is not feasible, such as in our case where the patient could not monitor INR due to remote access. Some data support the benefits of selective thrombolysis and endovascular thrombectomy in patients with severe CVST and worsening neurological symptoms despite heparin use [3,22]. On imaging, patients developing cerebral venous congestion or cerebral edema also benefit from selective thrombolysis and endovascular thrombectomy [3,7,26]. The prognosis of CVST is better in women with identifiable risk factors than women with no identifiable risk factor or men [1].

The management of ET requires risk stratification. The role of low-dose aspirin as a prophylactic antithrombotic agent is established, though with an increased risk of minor bleeding [23,24]. Aspirin monotherapy is used in low and intermediate-risk diseases without cardiovascular risk factors. Patients with CVST associated ET are considered to have high-risk disease irrespective of their age [3,12]. Hydroxyurea is the drug of choice for cytoreduction. It is used with aspirin in high-risk diseases with a history of thrombosis or positive JAK2 mutation and intermediate-risk disease with cardiovascular risk factors. HU decreases the risk of early thrombotic events and decreases the leukocyte activation responsible for inducing a hypercoagulable state in ET [25,26]. There is a 3.5% increased risk of leukemia in ET patients treated with HU alone [27]. Due to its leukemogenic and mutagenic potential, hydroxyurea is administered only if the benefits outweigh the risk of acute hemorrhage. New oral anticoagulants (NOACs) such as Rivaroxaban are being studied for their safety and efficacy in CVST. Currently, the data is limited to case reports, retrospective studies, and small trials. However, the results concerning efficacy seem to be similar to warfarin in CVST [17–19]. A recent systematic review has reported adequate efficacy and safety of NOACs compared to warfarin in CVST, with uncertainties persisting in dosing and duration of treatment [20]. Bose et al. reported the mean duration of 8.1 months for NOACs compared to 9.8 months with standard therapy [20]. However, current guidelines await more extensive randomized trials and meta-analyses on NOACs in CVST before adding them into its management guidelines [21]. Until more evidence is available, NOACs should be used in CVST in cases where warfarin use is not feasible, such as in our case where the patient could not monitor INR due to remote access. Some data support the benefits of selective thrombolysis and endovascular thrombectomy in patients with severe CVST and worsening neurological symptoms despite heparin use [3,22]. On imaging, patients developing cerebral venous congestion or cerebral edema also benefit from selective thrombolysis and endovascular thrombectomy [3,7,26]. The prognosis of CVST is better in women with identifiable risk factors than women with no identifiable risk factor or men [1].

The management of ET requires risk stratification. The role of low-dose aspirin as a prophylactic antithrombotic agent is established, though with an increased risk of minor bleeding [23,24]. Aspirin monotherapy is used in low and intermediate-risk diseases without cardiovascular risk factors. Patients with CVST associated ET are considered to have high-risk disease irrespective of their age [3,12]. Hydroxyurea is the drug of choice for cytoreduction. It is used with aspirin in high-risk diseases with a history of thrombosis or positive JAK2 mutation and intermediate-risk disease with cardiovascular risk factors. HU decreases the risk of early thrombotic events and decreases the leukocyte activation responsible for inducing a hypercoagulable state in ET [25,26]. There is a 3.5% increased risk of leukemia in ET patients treated with HU alone [27]. Due to its leukemogenic and mutagenic potential, hydroxyurea is administered only if the benefits outweigh the risk of acute hemorrhage.
leukemia [28]. The evidence on the role of direct oral anticoagulation (DOACs) in MPD is still not well-established [29,30]. The mainstay of treatment of CVST associated ET is anticoagulation, initially with intravenous heparin or oral warfarin, then later on with long-term low-dose aspirin, and cytoreduction with hydroxyurea (HU) [3,10,11,12]. The overall prognosis remains good with anticoagulation and cytoreduction. However, neurologic complications can persist [3]. Due to less mutagenic and more negligible pro leukemic effect, long-term low-dose aspirin, and cytoreduction with hydroxyurea (HU) [3, 10, 11, 12]. The overall prognosis remains good with anticoagulation and cytoreduction. However, neurologic complications can persist [3].

4. Conclusion

In patients presenting with CVST and persistent thrombocytosis, myeloproliferative disorders should be investigated as a possible cause of thrombosis.

Conflict of interest

None of the authors have any conflict of interest to declare.

Financial disclosure

None.

Consent

Written informed consent was taken from the patient before the submission of the article.

Author contributions

QY: Case identification, literature review, manuscript writing. HK and AK: Data collection, literature review, manuscript writing. FA and ZY: Supervision, literature review, revisions and editing in the manuscript. All authors reviewed and approved the final version of the manuscript.

Acknowledgment

This work was supported by the Qatar National Library (QNL).

References

[1] J.M. Coutinho, J.M. Ferro, P. Chanhao, F. Barinagarrementeria, C. Castru, M. G. Bouser, J. Stam, Cerebral venous and sinus thrombosis in women, Stroke 40 (7) (2009) 2356–2361.
[2] R. Behrouzi, M. Punter, Diagnosis and management of cerebral venous thrombosis, Clin. Med. (Lond.) 18 (1) (2018) 75–79.
[3] W.B. Chen, X.L. Wang, Cerebral venous sinus thrombosis as first manifestation of essential thrombocytocenia, Rinsho Shinkeigaku 44 (4) (2004) 34–38.
[4] R. Benzle, H. Mechal, H. Ziauddin, A. Rous, M.E.G. Benouna, A. Drigh, R. Habib, Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report, J. Med. Case Rep. 15 (1) (2021) 76.
[5] A.W. Jensen, A. Tefferi, C.A. Arndt, Cerebral venous sinus thrombosis associated with essential thrombocytocenia in a pediatric patient, J. Pediatr. Hematol. Oncol. 29 (3) (2007) 156–159.
[6] H. Kurosawa, M. Okuya, T. Matushita, T. Kubota, K. Endoh, S. Kuwashima, S. Hagisawa, Y. Sato, K. Fukushima, K. Sugita, Y. Okada, M.J. Park, Y. Hayashi, O. Arioka, JAK2V617F mutation-positive childhood essential thrombocytocenia associated with cerebral venous sinus thrombosis, J. Pediatr. Hematol. Oncol. 31 (9) (2009) 678–680.
[7] O. Mousouak, M. Aloufi Faris, M. Benabdejlil, S. Tizniti, F. Belahsen, Cerebral venous sinus thrombosis secondary to essential thrombocytocenia, Rev. Neurol. (Paris) 163 (5) (2007) 596–598.
[8] A. Arédi, C. Csecchetti, A. Colombo, L. Cattaneo, P.E. Fiotteli, E.M. Pogliani, E. M. Ellis, Neurological symptoms in essential thrombocytocenia: impact of JAK2V617F mutation and response to therapy, Eur. J. Haematol. 96 (5) (2016) 593–601.
[9] J. How, A. Zhou, S.T. O’H, Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease, Ther. Adv. Hematol. 8 (3) (2017) 107–118.
[10] E.S. Kristoffersen, C.E. Harper, K.G. Vetvick, S. Zarnovichy, J.M. Hansen, K.W. Faiz, Incidence and mortality of cerebral venous thrombosis in a Norwegian population, Stroke 51 (10) (2020) 3025–3029.
[11] S. Esmaili, M. Abolmaali, S. Araabi, M.R. Motamed, S. Chaiabakhsh, M. T. Johgata, M. Mojtahed, Z. Mirzaasgari, Rivaroxaban for the treatment of cerebral venous thrombosis, BMC Neurol. 21 (2) (2021) 73.
[12] C. Geinbisch, D. Richter, C. Herweh, P.A. Ringleb, S. Nagel, Novel factor Xa inhibitor for the treatment of cerebral venous sinus and sinus thrombosis, Stroke 45 (8) (2014) 2469–2471.
[13] M. Wasay, M. Khan, H.M. Rajput, S. Farooq, M.I. Memon, S.A. AlRutun, A. Malik, F. Abd-Allah, R.F. Shawaib, R. Shadi, S. Nishat, A. Saur, Direct oral anticoagulants versus warfarin in cerebral venous thrombosis: a multi-center, observational study, J. Stroke 21 (2) (2019) 220–223.
[14] G. Bose, J. Graveline, V. Vengandramur, R. Shorr, D.A. Fergusson, G. Le Gal, J. Coutinho, M. Mendonec, M. Viana-Baptista, S. Nagel, D. Dowlatshahi, Direct oral anticoagulants in treatment of cerebral venous sinus thrombosis: a systematic review, BMJ Open 11 (2) (2021), e040212.
[15] L. Ulivi, M. Squitieri, H. Cohen, P. Cowley, D.J. Werring, Cerebral venous thrombosis: a practical guide, Pract. Neurosurg. 20 (5) (2020) 356–367.
[16] F.V. Tsai, V. Kostanian, M. Rivero, K.W. Lee, C.C. Chen, T.H. Nguyen, Cerebral venous congestion as indication for thrombolytic treatment, Cardiovasc. Intervent. Radiol. 30 (4) (2007) 675–687.
[17] P.J. van Genderen, P.G. Mulder, M. Walseboer, D. van de Moerdijk, J.J. Michiels, Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin, Br. J. Haematol. 97 (1) (1997) 179–184.
[18] R. Landolfi, L. Di Gennaro, L. Navares, C. Patrano, Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies, Semin. Thromb. Hemost. 32 (3) (2006) 251–259.
[19] A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini, M. Balico, S. Marinari, G. Finazzi, C. Cerletti, T. Barbui, Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera, Blood 96 (13) (2000) 4261–4266.
[20] M. Benkerrou, C. Delarche, L. Brahimi, M. Fay, E. Vilmer, J. Elion, M.A. Gougerot-Pocidalo, C. Elbim, Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia, Blood 99 (7) (2002) 2297–2303.
[21] Y. Sterkers, C. Preudhomme, J.L. Laï, J.L. Demory, M.T. Caulier, E. Wattel, D. Bordessoule, F. Bauters, P. Fenaux, Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion, Blood 101 (2003) 1599–1613.
[22] A. Tefferi, T. Barbui, Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management, Am. J. Hematol. 95 (12) (2020) 1599–1613.
[23] J. How, C. Story, S. Ren, D. Neuberg, R.P. Rosovsky, G.S. Hobbs, J.M. Connors, Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients, Blood Cancer J. 11 (11) (2021) 176,